Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (ARMP) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ARMP · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Armata Pharmaceuticals, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
ARMP insider buying and selling by quarter
ARMP insider selling · ARMP insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · ARMP ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ARMP executive sell shares · ARMP board member insider trading · ARMP insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 14, 2026 | Kyme Pierre Chief Business Officer | Other | 1,030 | $11K | Form 4 |
| Mar 14, 2026 | Birx Deborah CEO · Director | Other | 4,919 | $52K | Form 4 |
| Jul 10, 2025 | Birx Deborah CEO · Director | Other | 13,637 | $31K | Form 4 |
| Jul 10, 2024 | Birx Deborah CEO · Director | Other | 22,925 | $61K | Form 4 |
| Mar 14, 2025 | Birx Deborah CEO · Director | Other | 6,061 | $12K | Form 4 |
| Mar 14, 2025 | Kyme Pierre Chief Business Officer | Other | 1,027 | $2K | Form 4 |
| Mar 14, 2024 | Rychlik Richard Corporate Controller and PFO | Award | 10,000 | — | Form 4 |
| Mar 14, 2024 | Birx Deborah CEO · Director | Award | 60,000 | — | Form 4 |
| Dec 21, 2023 | Birx Deborah CEO · Director | Award | 200,000 | — | Form 4 |
| Mar 31, 2022 | Innoviva Strategic Opportunities LLC Director | Purchase | 5,385,208 | $26.93M⚡ | Form 4 |
| Feb 9, 2022 | Innoviva, Inc. Director | Purchase | 3,614,792 | $18.07M⚡ | Form 4 |
| Oct 29, 2021 | Innoviva, Inc. Director | Purchase | 1,212,122 | $4.00M⚡ | Form 4 |
| Mar 17, 2021 | Innoviva, Inc. Director | Purchase | 4,285,935 | $13.93M⚡ | Form 4 |
Kyme Pierre
Chief Business Officer
Date
Mar 14
Shares
1,030
Price
$10.54
Value
$11K
Rychlik Richard
Corporate Controller and PFO
Date
Mar 14
Shares
10,000
Price
—
Value
—
Innoviva Strategic Opportunities LLC
Director
Date
Mar 31
Shares
5,385,208
Price
$5.00
Value
$26.93M ⚡
Innoviva, Inc.
Director
Date
Feb 9
Shares
3,614,792
Price
$5.00
Value
$18.07M ⚡
Innoviva, Inc.
Director
Date
Oct 29
Shares
1,212,122
Price
$3.30
Value
$4.00M ⚡
Innoviva, Inc.
Director
Date
Mar 17
Shares
4,285,935
Price
$3.25
Value
$13.93M ⚡
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ARMP insider trading
ARMP insider trades
Armata Pharmaceuticals, Inc. (ARMP) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Birx Deborah (CEO · Director), Kyme Pierre (Chief Business Officer). Over the past 12 months, 2 insiders have filed transactions with the SEC. ARMP insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Armata Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ARMP insider trading · 5 questionsThe insiders of Armata Pharmaceuticals, Inc. (ARMP) include executives and directors such as Birx Deborah (CEO · Director), Kyme Pierre (Chief Business Officer), among others. Over the past 12 months, 2 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026